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892 The Journal of Thoracic and CardioObjectives: Induction therapy is an important treatment option in locally advanced
non–small cell lung cancer. F-18-fluorodeoxyglucose positron emission tomography
(FDG-PET) has an important role in initial staging. The aim of this study was to
assess the value of FDG-PET in restaging after induction therapy and in analyzing
tumor viability, nodal status, distant metastases, and prognosis.
Methods: Forty-seven patients with locally advanced non–small cell lung cancer
accepted for resection after induction therapy underwent FDG-PET. Images were
interpreted visually for mediastinal nodal status and metastatic spread. The FDG
accumulation in the tumor site was measured by using the maximum standardized
uptake value.
Results: Unexpected metastases were detected by means of FDG-PET in 9 patients.
Surgical intervention was not performed in 8 patients with confirmed metastases.
The rate of unexpected findings increased from complete radiologic remission (0%)
over partial remission (9%) to no change (67%). The standardized uptake value was
higher in tumors with (n  26) than in those without (n  11) histologic proof of
viability (6.4  5.3 vs 2.9  1.6, P  .006). All patients with standardized uptake
values of greater than 5.8 had viable tumors. Sensitivity, specificity, and negative
predictive value were 81%, 64%, and 58% for tumor viability and 50%, 88%, and
85% for persistent mediastinal disease. Median survival after resection was greater
than 56 months for patients with tumor standardized uptake values of less than 4 and
19 months for patients with standardized uptake values of 4 or greater (P  .001).
Conclusion: FDG-PET helps in the selection of patients for resection after induction
therapy. It can be used to detect unexpected distant metastases, especially after poor
response to induction therapy. Its high negative predictive value in mediastinal
restaging allows for omission of repeat mediastinoscopy. Tumor standardized
uptake value after induction is a prognostic factor.
Although approximately one third of patients with lung cancer canbe treated with primary resection, the majority present in anadvanced stage. Induction therapy with combinations of chemo-therapy and radiotherapy has been proved to be efficient in locallyadvanced stages of non–small cell lung cancer (NSCLC). It ap-pears to improve prognosis, and different protocols are currently
being investigated in prospective trials.1
The response to neoadjuvant therapy is commonly assessed by means of ana-
tomic imaging to document the change in size of malignant lesions. This fails to
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masses (eg, tumor viability). In laboratory studies the re-
sponse to chemotherapy or radiotherapy was detected ear-
lier on the basis of changes in glucose metabolism rather
than on the basis of size regression.2
Positron emission tomography (PET) with F-18-
fluorodeoxyglucose (FDG) visualizes the glucose metabo-
lism in vivo and is increasingly used in oncologic staging.3
The role of FDG-PET has been established in the initial
staging of lung cancer.4-6
Until now, only limited data were published on the perfor-
mance of FDG-PET in patients with lung cancer after induc-
tion therapy. Previous studies reported the potential ability of
FDG-PET to detect residual tumor viability,7-11 persistent me-
diastinal disease,7-9,11,12 and distant metastases.8 For the selec-
tion of patients about to undergo resection after induction, it is
essential to exclude distant metastases. To our knowledge,
there are no published data on the rate of unexpected distant
metastases detected by means of FDG-PET for restaging. Even
if FDG-PET provides prognostic information after initiation of
palliative chemotherapy13 or completion of conformal (chemo)-
radiotherapy,14,15 there are no reports on the prognostic rele-
vance of the preoperative FDG uptake in the residual tumor
after induction therapy of NSCLC.
Thus, we investigated the value of FDG-PET after comple-
tion of induction therapy. We did a comparison with respect to
unexpected distant metastases, viability of the residual tumor,
accuracy of nodal restaging, and postoperative survival.
Patients and Methods
Patients
The patient population consisted of 47 patients (32 men) with histo-
logically proved NSCLC. They were accrued from July 1998 through
September 2003 at the University Hospital Homburg. All patients
were recruited from ongoing prospective studies investigating the use
of multimodal treatment of locally advanced NSCLC and were ac-
cepted for resection before FDG-PET.
The patients’ median age was 60 years (range, 37-77 years).
Initial stages were IIB (T3 N0, n 3), IIIA (T1-3 N2, n 10) and
IIIB (n  34) defined by T2-3 N3 (n  9), or T4 (n  25).
Histology of the tumor was squamous cell carcinoma (n  24),
adenocarcinoma (n  20), large cell carcinoma (n  1), mucoepi-
dermoid carcinoma (n  1), and unspecified NSCLC (n  1).
All patients underwent initial staging procedures according to
current German recommendations,16 including anterior cervical
mediastinoscopy in 16 patients with suspected mediastinal lymph
node metastases. In 34 cases FDG-PET imaging had been per-
formed before therapy in the initial staging.
Tumor-specific therapy consisted of platinum-based cytostatic
chemotherapy in all but 1 patient with additional irradiation of the
tumor site and involved the mediastinum in 33 patients (45-68 Gy,
1-1.5 Gy/d, in 19 patients; 32 Gy, 2  2 Gy/d, in 14 patients). One
patient with initial stage T3 pN0 M0 disease received preoperative
irradiation without chemotherapy (48.6 Gy).
The Journal of ThoraciAssessment of Tumor Response
Treatment response of the primary tumor was documented by
means of computed tomographic (CT) imaging and, with invaded
airways, bronchoscopy after completion of the induction therapy
by using World Health Organization criteria for definition of
complete response, partial response, no change, and progressive
disease. By means of conventional staging, 3 patients had a com-
plete response, 35 had a partial response, and 9 had no change.
PET Imaging
All patients had whole-body FDG-PET imaging within a median of 5
weeks (range, 2-11 weeks) after completion of induction therapy.
After overnight fasting, the blood glucose level was determined to
ascertain a level of less than 160 mg/dL. The patients then received
250 MBq (range, 160-350 MBq) of 2-deoxy-2-[F-18]fluoro-D-
glucose (FDG purchased from Forschungszentrum Karlsruhe, Ger-
many, or f-con, Rendsburg, Germany). Imaging started 90 minutes
after injection and was performed as previously reported.17 The
images were visually interpreted for uptake in the primary tumor and
mediastinal lymph nodes and for evidence of metastatic spread. Two
board-certified nuclear medicine physicians analyzed film documen-
tations in all 3 planes and maximum intensity projections in cine
mode. Semiquantitative evaluation was based on standardized uptake
values (SUVs) calculated as the ratio of measured activity concentra-
tion over an assumed homogenous distribution of the applied radio-
activity in the whole body. The peak SUV in the tumor site was
measured by using a region-of-interest technique with the standard
image analysis software of the PET scanner (ECAT version 7.2). For
evaluation of the mediastinal lymph nodes, circular regions of interest
with a diameter of 1 cm were defined in the hilar and mediastinal
lymph node stations according to the method of Mountain and
Dresler,18 and the peak SUV was measured. Lesions with SUVs of
greater than 2.5 were considered malignant because this value usually
exceeds the normal level in the mediastinal blood pool.19
Surgical Intervention
In 37 patients resection and systematic lymph node dissection was
performed after induction therapy within a median of 2 weeks
(range, 1-6 weeks) after the FDG-PET scan. A typical lobectomy
was performed in 17 patients, and 3 patients underwent lobectomy
and chest wall resection. A sleeve lobectomy was required in 12
patients, and 3 had a bronchovascular sleeve resection, reflecting
our policy of avoidance of pneumonectomy in central tumors.20
Pneumonectomy was necessary in 2 patients. All of these proce-
dures were combined with a systematic lymphadenectomy. Rou-
tine pathologic examination of the surgical specimens was per-
formed according to current recommendations.21
Statistics
Numerical values are reported as medians with ranges and are
compared between groups by the Wilcoxon U test. Proportions are
reported as percentages with 95% confidence intervals (95% CIs).
The frequency of unexpected distant metastases for patients with
no change, a partial response, and no change was compared by
using the Somers D test. The difference in patients with and
without a previous PET scan was analyzed with the Fisher exact
test. Contingency tables of true-negative, false-negative, true-pos-
itive, and false-positive findings have been constructed for the
c and Cardiovascular Surgery ● Volume 128, Number 6 893
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and lymph node staging. Diagnostic performance parameters (sen-
sitivity, specificity, accuracy, negative predictive value [NPV], and
positive predictive value) were derived from these contingency
tables. The McNemar test was used to compare diagnostic perfor-
mance parameters between different diagnostic modalities.
Survival data were obtained from follow-up contacts or from
telephone interviews of the patients’ local physicians. The observation
period ended in December 2003. Survival was analyzed for patients
without distant metastases who underwent resection. Survival time
was calculated with the Kaplan-Meier method. Survival differences
between groups were compared by using the log-rank test.
Results
Unexpected Metastases
After induction therapy, FDG-PET showed findings consis-
tent with unexpected metastases in 9 instances (2 liver, 1
bone, 1 adrenal, 1 spleen, 1 soft tissue, 1 thoracic wall
lymph node, 1 supraclavicular lymph node, and 1 axillary
lymph node). In 8 patients the findings were confirmed by
means of histology (n 4) or serial imaging (n 4). These
patients did not undergo resection. A typical case is illus-
trated in Figure 1. The rate of unexpected confirmed me-
tastases was 8 of 47 (prevalence 17%). In 1 patient the
false-positive FDG accumulation in an axillary lymph node
could not be confirmed as being caused by malignancy. One
false-negative finding occurred in a patient with a brain
metastasis outside the field of view of the PET scan, which
became symptomatic after the restaging procedures. No
significant difference was found for the frequency of distant
metastases in patients with (4/34 [15%]) or without (4/13
Figure 1. Initial (left) and restaging (right) FDG-PET of a patient
with an unexpected soft tissue metastasis after inductive che-
moradiotherapy of an adenocarcinoma of the right lower lobe
(initial stage T4 pN2 M0). Conventional restaging showed partial
remission, but the planned tumor resection was cancelled after
histologic confirmation of malignancy in the FDG-accumulating
lesion in the right shoulder.[31%]) an FDG-PET scan for initial staging (P  .198).
894 The Journal of Thoracic and Cardiovascular Surgery ● DeceThere was a significant correlation between the fre-
quency of unexpected metastases detected by means of
FDG-PET and the tumor response evaluated by conven-
tional imaging (Figure 2). The rate increases from complete
response over partial response to no change (P  .003).
Viability of Residual Tumors
Resection of the primary tumor was performed in 37 pa-
tients. Two patients refused surgical intervention.
In the 2 patients with complete response (determined by
conventional imaging criteria), no viable tumor cells were
found in the specimen. Two of 3 patients with no change
had viable tumor cells. In patients with a partial response,
24 had residual tumor cells, and in 8 patients no viable
tumor was found. Overall, tumor viability was seen in the
specimens in 26 of 37 surgical patients. In 11 patients there
was no histologic proof of a viable tumor.
The glucose metabolism in viable residual tumors was
higher (P .006) than in tumors without histologic proof of
viable cells (Table 1). All primary tumors with an SUV of
5.8 or more contained viable tumor cells. PET findings were
false negative in 5 instances of microscopic tumor residual
tumor (n  4) and bronchioloalveolar carcinoma (n  1).
False-positive PET findings occurred after irradiation (n 
3) or for a brief period (17 days) after the last chemotherapy
cycle (n  1). Diagnostic test parameters for viability with
an SUV threshold of 2.5 were a sensitivity of 81% (95% CI,
61%-93%), a specificity of 64% (95% CI, 31%-89%), an
accuracy of 76% (95% CI, 59%-88%), a positive predictive
value of 84% (95% CI, 64%-95%), and an NPV of 58%
(95% CI, 28%-85%).
Assessment of Mediastinal Nodal Status
A total of 131 lymph node stations were removed during
thoracotomy (3.6 per patient), including 78 mediastinal sta-
tions. Viable tumor cells were found in 11 samples (median
SUV, 3.8; range, 2.0-8.9) of 8 patients. Visual interpretation of
FDG-PET resulted in 7 true-positive, 4 false-negative, 64 true-
negative, and 3 false-positive findings for the mediastinal
lymph node stations. Using quantitative criteria, assuming ma-
lignancy in lymph nodes with SUVs of greater than 2.5, we
observed 7 true-positive, 4 false-negative, 53 true-negative,
and 14 false-positive findings. This approach did not increase
the number of detected lymph node metastases compared with
quantitative analysis but rather increased the rate of false-
positive findings.
The patient-based analysis showed that visual interpre-
tation of FDG-PET correctly detected residual mediastinal
disease in 4 patients or excluded residual mediastinal dis-
ease in 22 patients. In 4 patients the presence of solitary
mediastinal lymph node involvement was missed, and false-
positive findings occurred in 3 patients. Two patients were
excluded from analysis because of incomplete mediastinal
mber 2004
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eral nodes. The diagnostic test parameters for the patient-
based analysis and for qualitative and quantitative nodal
analysis are summarized in Table 2. Although we observed
no difference in the sensitivities of quantitative nodal anal-
ysis, the specificity of visual interpretation is higher than
that of quantitative analysis of lymph node involvement by
means of FDG-PET (McNemar test, P  .001).
Survival
The median follow-up duration was 36 months (range, 1-63
months). Two patients were lost to follow-up since dis-
charge from the hospital after surgical intervention. During
the observation period, 14 of the 35 remaining patients died.
The estimated median survival for the total group was 38
months from the date of the operation. The estimated me-
dian survival (Figure 3) was longer for patients with SUVs
of less than 4 in the residual tumor than for those with SUVs
of 4 or greater (56 months vs 19 months, P  .001).
Discussion
Multimodal treatment concepts have become a therapeutic
option for patients with stage IIIA NSCLC. Even in patients
with stage IIIB disease, current investigations indicate that
operations after induction treatment can prolong survival.22
Different combinations of induction therapy with chemo-
therapy, radiotherapy, or both, followed by surgical resec-
tion, are currently under investigation.1
The reevaluation of tumor viability and metastatic spread
remains a challenge for anatomic imaging because the re-
duction of tumor size, which does not occur immediately
Figure 2. Rate of unexpected distant metastases for pa
and no change (NC). The frequency of unexpected fi
evaluated by means of conventional imaging.tients with complete response (CR), partial response (PR),
ndings correlates inversely with the tumor response, asafter cell death, is used as a diagnostic criterion. The use of
The Journal of ThoraciTABLE 1. FDG accumulation reported as median SUV in
primary tumor sites after completion of induction therapy
Response from
CT imaging
Viable tumor No viable tumor cells
SUV Patients SUV Patients
CR NA n  0 1.9 (1.7-2.2) n 2
PR 4.7 (2.0-21.6) n 24 2.0 (1.2-5.8) n 8
NC 11.8 (8.3-15.2) n 2 3.5 n  1
All patients 4.8 (2.0-21.6) n 26 2.2 (1.2-5.8) n 11
Figures in parentheses are ranges. FDG, F-18-fluorodeoxyglucose; SUV,
standardized uptake value; CT, computed tomographic; CR, complete re-TABLE 2. Diagnostic test parameters for mediastinal lymph
node restaging for different types of analysis
Test
Patient based,
visual
Nodal analysis,
quantitative
Nodal analysis,
visual
Sensitivity (%) 50 (16-84) 64 (31-89) 64 (31-89)
Specificity (%) 88 (69-97) 79 (67-88) 96 (87-99)
Accuracy (%) 79 (61-91) 77 (66-86) 91 (82-96)
PPV (%) 57 (18-90) 33 (15-57) 70 (35-93)
NPV (%) 85 (65-96) 93 (83-98) 94 (86-98)
Patient-based analysis evaluates whether FDG-PET correctly assigns the
N stage with residual mediastinal involvement and compares the stages
N0/N1 versus N2/N3 for each patient. Nodal analysis is used for compar-
ison of F-18-fluorodeoxyglucose positron emission tomography findings
with histopathology in each mediastinal biopsy specimen. Proportions are
reported as percentage values with lower and upper bounds of the 95%
confidence interval. PPV, Positive predictive value; NPV, negative predic-
tive value.
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tinoscopy is limited because it remains incomplete in up to
40% of patients because of fibrosis and adhesions.22
FDG-PET has been shown to be the most accurate non-
invasive imaging modality in the initial staging of NSCLC.4
The role of PET in the restaging of NSCLC is not yet clear.
Several clinical studies focusing on single aspects of PET
have been published.7-14 Conflicting data have been pub-
lished regarding sensitivity and specificity in mediastinal
lymph node involvement,7-9,11,12 and the prognostic effect
of PET results is unclear.
One important ability of FDG-PET is the detection of
unexpected distant metastases. Consistent with the study of
Akhurst and colleagues,8 we were able to detect all distant
metastases after induction therapy. Unexpected metastases
were present in 17% of our patients, some of them at
unusual sites (eg, soft tissue, spleen, and thoracic wall
lymph node). These are not covered by recommended im-
aging procedures16 or easily missed on routine CT scan
interpretation.
It might be argued that these metastases had been present
already before induction treatment and should have been
detected during pretreatment PET scanning. We did not
perform a PET investigation in all patients before induction,
but there was no difference in the frequency of unexpected
metastases between patients with or without an initial PET
scan. Therefore the lesions might be of more recent origin.
The incidence of 17% in our cohort is similar to the FDG-
Figure 3. Survival probability data for patients after resection of
residual tumor after induction therapy. The survival of patients
with an FDG uptake in the residual primary tumor with an SUV of
4 or greater is shorter than for patients with SUVs of less than 4
(log-rank test, P  .0006).PET results of unexpected distant metastases in 20% of
896 The Journal of Thoracic and Cardiovascular Surgery ● Decepatients with NSCLC to undergo radical radiotherapy.23
The rate has been shown to increase with pre-PET clinical
stage from 8% for stage I through 18% for stage II to 24%
for stage III.23 Similarly, we observed an increasing fre-
quency of distant metastases with poor tumor response, as
assessed on the basis of conventional size criteria. This
reached an incidence of 67% in patients with a clinical
response of no change.
Regarding the assessment of tumor viability, our results
are in line with previous reports on FDG uptake after
induction therapy of NSCLC.7-9,11 Akhurst and colleagues8
reported a sensitivity of 90% and a specificity of 67% for
the detection of tumor viability by means of FDG-PET.
Similarly, Cerfolio and coworkers9 found corresponding
values of 97% and 100%, and Ryu and associates7 docu-
mented values of 88% and 67%. In the most recent report a
sensitivity of only 58% and a specificity of 100% are
published for FDG-PET performed 2 weeks after the com-
pletion of chemotherapy.11
In our series we mainly observed false-positive findings
after radiotherapy. Irradiation is well known to induce such
changes.24 FDG-PET reading was compared with a recent
CT image to minimize the chance of misinterpretation. On
the other hand, we saw false-negative findings, primarily in
small tumors and bronchioloalveolar carcinoma. Similar
observations have been published for the initial evaluation
of lung lesions.4 The sensitivity of FDG-PET in restaging is
limited by the size of malignant tissue required for detec-
tion, whereas histologically, the existence of only a single
tumor cell can be regarded as a sign of viability.
For mediastinal restaging, we analyzed the lymph node
stations by means of visual interpretation, as well as quan-
titative measurement. The specificity of visual interpretation
was higher than that of quantitative analysis, without any
difference in sensitivity. This can be explained by the fact
that small deviations in mediastinal blood pool radioactivity
can exceed the SUV threshold of 2.5, which can lead to
false-positive findings. The visual analysis additionally uses
the shape of activity distribution, interpreting lesions of
focally increased FDG uptake as malignant.
In a previous investigation on FDG-PET and mediasti-
noscopy during initial staging of lung cancer, we found a
median SUV of 7.3 (range, 1.6-18.9) in metastatic medias-
tinal lymph nodes.17 This was higher than the SUV in
lymph node metastases after induction therapy in this study
(median SUV, 3.8; range, 2.0-8.9; P .046). The difference
might be due to decreased metabolism or the amount of
malignant tissue. These factors might also explain the re-
duced sensitivity of PET.
Our results in mediastinal restaging by means of FDG-
PET are similar in diagnostic performance to the data pub-
lished by Akhurst and colleagues8 and Ryu and associates.7
We cannot confirm the observation of Cerfolio and cowork-
mber 2004
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cheal lymph nodes because we observed 2 false-negative
findings in the paratracheal and 2 false-negative findings in
the infracarinal stations. Nevertheless, the overall diagnostic
performance of their study compares with that of ours.
The results of PET have to be compared with those
published for repeat mediastinoscopy. After initial medias-
tinoscopy and induction treatment, this procedure can be
technically difficult. Because of inflammatory changes,
lymph nodes might be difficult to locate.25,26 Repeat medi-
astinoscopy has been shown to result in a sensitivity of only
50% after induction therapy of stage IIIB NSCLC.22 The
NPV was reported to be 71%. This is similar to the 85%
NPV of FDG-PET with respect to mediastinal lymph node
metastases in our patient-based analysis.
FDG uptake in NSCLC has been identified as a prog-
nostic parameter at initial presentation,6,27,28 early after the
initiation of chemotherapy,13 during radiotherapy, or after
completion of tumor treatment.14,29,30 Our analysis is the
first to show that the preoperative FDG uptake in the resid-
ual tumor after induction is a prognostic parameter with a
significant correlation to survival.
There are several potential limitations of our study in that
it is a retrospective investigation, and the number of patients
studied is limited. Because surgical treatment of stage III
NSCLC is not standard treatment, the accrued patients were
selected from ongoing studies. This explains a high propor-
tion of individuals with initial stage IIIB disease and the use
of different induction schemes.
In left-sided resections lymph node dissection only reached
ipsilateral hilar and mediastinal nodes, so that there is no
pathologic analysis of the contralateral lymph node stations.
The timing of the FDG-PET and the completion of
induction varied between patients, with a median interval of
5 weeks and a range of 2 to 11 weeks. Presently, there are
no systematic data available on patients with NSCLC to
determine the optimal time to assess residual malignant
tissue after induction therapy. The interval, however, might
have an effect on sensitivity. Port and coworkers11 used an
interval of 2 weeks after induction chemotherapy and found
the lowest sensitivity of all studies in this field.
As a recommendation for the time point of repeat FDG-
PET, we suggest an interval of at least 2 weeks after
completion of induction therapy to achieve a sufficient
sensitivity in the detection of residual viable tumor and to
avoid inflammatory therapy–induced reactions.
FDG-PET could become the standard of care after induc-
tion therapy because it helps in the selection of patients for
resection caused by the detection of unexpected distant metas-
tases, especially in patients with poor response. Compared with
initial staging, the sensitivity in the detection of the primary
tumor and of lymph node metastases is slightly reduced. The
high NPV of FDG-PET in mediastinal restaging justifies omis-
The Journal of Thoracision of repeat mediastinoscopy if the mediastinum is PET
negative. After induction therapy, the preoperative FDG up-
take in NSCLC provides a prognostic parameter.
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Discussion
Dr Robert J. Cerfolio (Birmingham, Ala). This topic is both
clinically important and relevant. I think that as general thoracic
surgeons, we are going to see more and more patients who are
undergoing neoadjuvant therapy, and we are going to be faced with
the increasing challenge of choosing who is best brought to the
surgical arena for attempted curative resection after therapy, and
that decision is going to be based on what are relatively inaccurate
restaging modalities. We do not believe the most recent article in
The New England Journal of Medicine in January that showed that
a very, very modest 5% increase in survival with adjuvant chemo-
therapy is going to swing the pendulum away from neoadjuvant
therapy but rather toward more adjuvant therapy. Thus I think this
article is important.
898 The Journal of Thoracic and Cardiovascular Surgery ● DeceFor time’s sake, I am going to get right to my questions. I will
give them to you one at a time. I have 3 sets of questions, but they
are on just 3 basic topics. As you know, and you and I have talked
about this, we have some data showing that the maximum SUV is
an independent and better predictor of survival than the current
TNM classification system for lung cancer. In addition, we have
found that the percentage change in the maximum SUV on a repeat
PET is a predictor of pathologic response, prognosis, and survival,
with an 80% decrease in the maximum SUV after neoadjuvant
therapy as a marker of complete pathologic response. In your
article you examined the absolute value of the repeat PET with the
SUV. Thirty-three of your 47 patients had an initial PET. Can you
tell us whether you examined the percentage change in the max-
imum SUV, and did it correlate with the complete response rate,
survival, or both?
Dr Graeter. Thank you for your kind remarks. We had a
preinduction therapy PET in about 75% of the patients, and 25 of
those 37 underwent operations. For those patients with nonviable
tumors, the reduction was about 85%. We then compared those
with a reduction of more than 80% and those with a reduction of
less than 80%, but although the difference was about 40% in
survival at 4 years, this did not reach a significant level.
Dr Cerfolio. Several reports have shown that a repeat PET scan
can be difficult to interpret, especially if it is performed too soon
after neoadjuvant radiotherapy, for example, within 2 or 3 weeks,
and also that the higher the dose of the preoperative radiation, the
more difficult it can be to interpret a repeat PET scan. Did you
examine the accuracy of repeat PET scanning for different doses of
radiotherapy, and can you tell us what you believe is the best time
frame for performing a repeat PET scan after the completion of
neoadjuvant therapy, especially radiotherapy?
Dr Graeter. All of these patients were acquired from ongoing
induction therapy studies, and therefore they had a fairly uniform
dose of between 50 and 55 Gy. Therefore the study was not really
useful at differentiating whether 50 Gy is better than 55 Gy. But
what we do know and what is published is that within the first 2
weeks, radiation leaves a lot of inflammatory changes, and that
makes a PET scan very difficult to interpret. After 4 weeks, we
hardly see any problems with that.
Dr Cerfolio. Do you recommend 4 weeks?
Dr Graeter. We recommend 4 weeks. Also, we had 2 groups,
one with radiation and one with chemotherapy only, and radiation
did not make any difference in the sensitivity parameters later on
after 4 weeks.
Dr Cerfolio. My final question concerns the high number of
patients with stage IIIB disease in this article, and I want to
specifically focus on those who had N3 disease. It is a little
different than most of our manuscripts would be. Many of us
believe that recalcitrant N2 or N3 disease is a relative contraindi-
cation for thoracotomy and resection, as Dr Miller mentioned in
the previous paper. Do you share this opinion, and if you do, how
do you test for recalcitrant N3 disease? Do you do repeat medi-
astinoscopy, repeat endoscopic ultrasonography, or repeat video-
assisted thoracoscopic surgery, or was the repeat PET scan and the
change in the maximum SUV taken as the gospel truth? If so, then
the contralateral lymph node really was never pathologically ex-
amined because you were in a different chest.
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TSDr Graeter. This is a difficult question. Repeat mediastinos-
copy is associated with a sensitivity of about 50% and an NPV that
is equally poor, as published in the Annals about 2 years ago. We
believe that in PET, if we have a low SUV in the contralateral
lymph node and we do not have any sign of progressive disease,
we will go ahead and operate.
Dr Mark J. Krasna (Baltimore, Md). Just to follow up on Dr
Cerfolio’s point, it would seem to me at this point premature to
preclude somebody from undergoing surgical intervention if a PET
scan was positive unless you proved it was positive pathologically.
I would like to reiterate that I think it would also be premature to
assume in somebody with an N3 tumor that it is okay to go ahead
and do the resection because their PET results are now negative.
As you showed, there are a significant number of false-negative
and false-positive results. In those 2 scenarios I think you need to
take that into consideration. Our policy has been to do contralateral
video-assisted thoracoscopic surgery for those patients who have
suspected N3 disease with an excellent yield. If you do not want to
do a remediastinoscopy on those patients who have a persistent
positive or suspicious spot on the PET scan, one should consider
whether you want to actually restage that patient surgically before
going ahead with a resection. Again, the pictures were beautiful,
but if you have one single dot left out of those four, you need to
make sure that that is the one you are going to sample. If you just
sample the higher one or the lower one and that was the negative
one, you might be missing the important finding.
My last comment goes to an interesting paper that came out last
year from Europe on esophageal cancer. I wonder whether you
have had any experience doing a repeat PET scan after the first
cycle of chemotherapy in patients with neoadjuvant chemotherapy
for esophageal cancer. This ended up being a predictor in that
institution for outcome and complete pathologic response rate.
Because not all of your patients had a PET pretreatment, did any
of them have another PET scan before that final one, or was it just
one at the very end?
Dr Graeter. For this analysis, we only used postinduction
therapy PET scanning, but we did a multivariate analysis with
TNM stage, type of tumor, radiation, yes, no, everything you can
think of, and the only thing that really came out of it significantly
was an SUV of greater than or less than 4 as a prognostic param-
eter for this group. In addition to your comment, if a PET scan is
positive, we think that you always have to perform a biopsy before
you take the next step. That is very important.
Dr Raphael Bueno (Boston, Mass). Our distribution of lung
cancers in North America is a little different than in Europe in that
you have more squamous carcinomas and we have more adeno-
carcinomas. Has the incorrect PET prediction that you have re-
ported been mostly in any particular subtype of lung cancer, or
were the patient numbers insufficient to determine that issue?
Dr Graeter. Actually, the only type we really have problems
with is bronchoalveolar carcinoma, and that is well known for the
primary staging, too.
Dr Nasser K. Altorki (New York, NY). My colleagues and I
have just recently looked at the value of PET after induction
chemotherapy and found that the NPV was very poor. The obvious
concern here is that a negative PET scan after induction chemo-
therapy does not necessarily equal a complete pathologic response,
yet that is precisely how it is generally perceived in the radiation
The Journal of Thoraciand medical oncology worlds. I was wondering whether you found
that the NPV differed whether your therapy was preoperative
chemotherapy or preoperative chemoradiation. Did you look at
that?
Dr Graeter. No, I did not. The values were almost the same.
That is why I did not bring them up here. There was not much
difference.
Dr David J. Sugarbaker (Boston, Mass). We have been in-
terested at the Brigham in the ability to restage surgically patients
treated with induction therapy, and there was a trial published
some years ago from the CALGB, one of our clinical trials groups,
that was a trial of patients with positive IIIA disease determined by
means of mediastinoscopy, induction chemotherapy only, fol-
lowed by surgical intervention, and when we analyzed the data, the
patients who were living a long time were those who had been
downstaged, whose mediastinal nodes once proved positive by
means of biopsy had now become negative. We thought that was
a marker of the biologic response of that tumor to the chemother-
apy. That was about 30% of the patients who had been downstaged
with this particular chemotherapy regimen, and therefore the ma-
jority had not been. I wonder whether you could comment on the
role of radiotherapy as a potential confounder of the interpretation
of mediastinal nodes after induction therapy in the use of PET in
the way that you have described.
Dr Graeter. Radiation therapy did not have any influence on
the outcome, irrespective of whether patients received radiation
therapy. It also did not matter whether patients had any viable
tumor left.
Dr Sugarbaker. I am not talking about the primary tumor. I am
talking about the lymph nodes, the mediastinal nodes. Therefore, it
did not matter in terms of prognosis whether there was residual
tumor in the mediastinal nodes, is that what you said?
Dr Graeter. I was talking about the primary tumor right now.
Dr Sugarbaker. Okay.
Dr Graeter. The lymph nodes, it does matter, but again, it did not
come out as a significant prognostic factor in this smaller group.
Dr Bueno. What was the long-term survival in the IIIB group?
Dr Graeter. It was about 65% if the SUV was less than 4.
Dr Bueno. But how long? What is the median survival?
Dr Graeter. For the 16 patients that had SUVs of less than 4,
it was 57 months. For the IIIB group, it was about 55.
Dr Cerfolio. I will just make a comment. If Dr Miller at the
Southern accepts our abstract, we have some data that the amount
of radiation does indeed make a difference, and we do not predict
the mediastinal lymph nodes as well when we are at 60 Gy or
greater, but at 45 Gy we do, and we do not predict them as well if
we do a second PET scan within 3 weeks of the completion of
radiation. Therefore we think the dose does make it more difficult,
but again, that is a small series.
Dr Sugarbaker. Micrometastatic disease is what kills these
patients, you know, distant disease. Therefore, if you sterilize
the mediastinum, then the use of the mediastinal nodes revert-
ing to negative as an indicator or sentinel of the effectiveness of
chemotherapy on distant micrometastatic disease is gone. Then
everybody looks like they are downstaged, but then you are still
operating on the wrong patients because the majority of patients
with IIIA and IIIB disease die of distant disease. That was the
point.
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